<DOC>
	<DOCNO>NCT00924170</DOCNO>
	<brief_summary>BACKGROUND : - CD25 ( p55 , Tac IL2R alpha ) strongly express virtually 100 % patient adult T-cell leukemia/lymphoma ( ATL ) , highly aggressive HTLV-1 related malignancy respond poorly chemotherapy . - In ATL , humanize anti-CD25 monoclonal antibody ( Mab ) daclizumab produce 13-14 % response , anti-CD52 Mab Alemtuzumab ( Campath-1H ) produce response lasting great 2 month 30 % 23 patient . - LMB-2 anti-CD25 recombinant immunotoxin contain variable domain murine MAb anti-Tac truncate Pseudomonas exotoxin . - In phase I trial NCI , MTD LMB-2 40 microg/Kg IV give every day 3 dos ( QOD times 3 ) . LMB-2 induce great 90 % tumor reduction rapidly 3 ATL patient protocol , achieve 1 partial response due rapid tumor progression and/or immunogenicity . - In preclinical model , response recombinant immunotoxins limited high concentration soluble receptor blood especially interstitial space tumor . Synergism observe chemotherapy immunotoxins , possibly due reduction soluble receptor tumor interstitium . OBJECTIVES : -To determine , nonrandomized fashion , verify safety , fludarabine cyclophosphamide ( FC ) prior LMB2 ATL result low immunogenicity rate major response last great 2 month , may improvement demonstrate previously CAMPATH . Secondary objective : - To determine effect 1 cycle FC alone ATL . - To examine progression-free overall survival ATL FC/LMB-2 . - Evaluate pharmacokinetics , toxicity , monitor soluble CD25 tumor marker level serum . - To study effect LMB-2 plus FC normal B- T-cell subset FACS . ELIGIBILITY : - CD25 plus ATL , untreated prior therapy - ECOG 0-2 , ANC , platelets albumin least 1000 , 75,000 , 3.0 . DESIGN : - Fludarabine 25 mg/m ( 2 ) IV day 1-3 - Cyclophosphamide 250 mg/m ( 2 ) IV day 1-3 - LMB-2 30-40 micro g/Kg IV day 3 , 5 7 . - LMB-2 dose : Begin 30 microg/Kg time 3 . Escalate 40 microg/Kg DLT 0/3 1/6 30 microg/Kg . Continue 40 microg/Kg 0-1 6 DLT 40 microg/Kg . - Administer cycle 1 FC alone . Two week start cycle 1 , begin 6 cycle FC plus LMB-2 minimum 20-day interval . - Accrual goal : 29-37 patient , include 4 replacement ... .</brief_summary>
	<brief_title>Phase II Trial LMB-2 , Fludarabine Cyclophosphamide Adult T-Cell Leukemia</brief_title>
	<detailed_description>BACKGROUND : - CD25 ( p55 , Tac IL2Ra ) strongly express virtually 100 % patient adult T-cell leukemia/lymphoma ( ATL ) , highly aggressive HTLV-1 related malignancy respond poorly chemotherapy . - In ATL , humanize anti-CD25 monoclonal antibody ( Mab ) daclizumab produce 13-14 % response , anti-CD52 Mab Alemtuzumab ( Campath- 1H ) produce response last &gt; 8 week 30 % 23 patient . - LMB-2 anti-CD25 recombinant immunotoxin contain variable domain murine MAb anti-Tac truncate Pseudomonas exotoxin . - In phase I trial NCI , MTD LMB-2 40 mcg/Kg dose IV give every day 3 dos ( QOD x3 ) . LMB-2 induce &gt; 90 % tumor reduction rapidly 3 ATL patient protocol , achieve 1 partial response due rapid tumor progression and/or immunogenicity . - In preclinical model , response recombinant immunotoxins limited high concentration soluble receptor blood especially interstitial space tumor . Synergism observe chemotherapy immunotoxins , possibly due reduction soluble receptor tumor interstitium . OBJECTIVES : - To determine , nonrandomized fashion , verify safety , fludarabine cyclophosphamide ( FC ) prior LMB2 ATL result low immunogenicity rate major response last &gt; 8 week may improvement demonstrate previously CAMPATH . - Secondary objective - To determine effect 1 cycle FC alone ATL . - To examine progression-free overall survival ATL FC/LMB-2 . - Evaluate pharmacokinetics , toxicity , monitor soluble CD25 tumor marker level serum . - To study effect LMB-2 +FC normal B- T-cell subset FACS . ELIGIBILITY : - CD25+ ATL , untreated prior therapy , leukemic type without malignant mass &gt; 4 cm . - ECOG 0-2 , ANC , platelets albumin least 1000 , 75,000 , 3.0 respectively . DESIGN : - IV fludarabine cyclophosphamide ( FC ) day 1 3 ( dos list respectively ) - Patients 1-7 10-14 , &gt; 18 : 25 250 mg/m2/day - Patients 8-9 : 30 300 mg/m2/day - Patients 15-17 : 20 200 mg/m2/day - LMB-2 dose : Begin 30 mcg/Kg IV day 3,5 7 . Escalate 40 mcg/Kg DLT 0/3 1/6 30 mcg/Kg . Continue 40 mcg/Kg 0-1 6 DLT 40 mcg/Kg . - Administer cycle 1 FC alone . Two week start cycle 1 , begin 6 cycle FC plus LMB-2 minimum 20 day interval . - Accrual goal : 29-37 patient , include 4 replacement .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Diagnosis acute lymphomatous ATL flow cytometry blood immunohistochemistry biopsy tissue , confirm NCI Laboratory Pathology , previously treat unless patient ineligible refuse protocols treatment ATL . 2 . Neutralizing antibody less equal 75 % neutralization 200 ng/ml LMB2 . 3 . At least 18 year old . 4 . ECOG 02 . 5 . Able understand give inform consent . 6 . Negative pregnancy test female childbearing potential . 7 . The transaminase ALT AST must less equal 3times upper limit normal ( UNL ) less equal 10times normal due ATL . Albumin must great equal 3.0 gm/dL . Total bilirubin must less equal 1.5 mg/dL except patient Gilbert syndrome ( define great 80 percent unconjugated bilirubin ) must less 5mg/dl . 8 . Creatinine le 2.0 mg/dL . 9 . ANC great equal 1000/uL platelet great equal 50,000/uL . 10 . Current prior feature acute ( correct Ca++ &gt; 2.73 LDH 2 fold ULN ) chronic ( LDH 1.52fold ULN absolute lymphocyte count &gt; 4 x10^9/L Tcells &gt; 3.5 x10^9/L ) ATL . Patients smolder ATL ( acute chronic feature ) symptomatic ATL skin lesion also eligible . EXCLUSION CRITERIA : 1 . Prior therapy LMB2 . 2 . Central nervous system disease evidence clinical symptomatology . 3 . Cytotoxic chemotherapy , steroid Mab within 3 week enrollment , except anti Tac Mab ( i.e . daclizumab ) , use within 12 week enrollment . Hydroxyurea consider different cytotoxic chemotherapy may use day enrollment providing increase week prior enrollment patient disease burden decreasing time . 4 . Uncontrolled infection . 5 . Untreated uncontrolled 2nd malignancy . 6 . Patients pregnant breastfeeding . 7 . Patients HIV hepatitis C , since patient reduction normal T Bcells would increase risk exacerbation underlie disease . Patients would exclude hepatitis B surface antigen positivity Lamivudine Entecavir . 8 . Patients receive warfarin ( Coumadin [ R ] ) 9 . Patients leave ventricular ejection fraction le 45 % . 10 . Patients DLCO le 50 % normal FEV1 le 50 % normal . 11 . No concomitant use alternative complimentary therapy OTC agent allow without prior approval PI . 12 . Tumor lymph node mass &gt; 4 cm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 13, 2017</verification_date>
	<keyword>Immunotoxin</keyword>
	<keyword>CD25</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Neutralization</keyword>
	<keyword>Neutralizing Antibodies</keyword>
	<keyword>Adult T-Cell Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>ATL</keyword>
</DOC>